GB9721266D0 - Therapeutic use - Google Patents

Therapeutic use

Info

Publication number
GB9721266D0
GB9721266D0 GBGB9721266.6A GB9721266A GB9721266D0 GB 9721266 D0 GB9721266 D0 GB 9721266D0 GB 9721266 A GB9721266 A GB 9721266A GB 9721266 D0 GB9721266 D0 GB 9721266D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic use
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9721266.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Priority to GBGB9721266.6A priority Critical patent/GB9721266D0/en
Publication of GB9721266D0 publication Critical patent/GB9721266D0/en
Priority to PCT/GB1998/001178 priority patent/WO1998047514A1/en
Priority to JP54529998A priority patent/JP2001523245A/en
Priority to CA002287397A priority patent/CA2287397A1/en
Priority to EP98917442A priority patent/EP0977573A1/en
Priority to US09/403,519 priority patent/US6162805A/en
Priority to AU70671/98A priority patent/AU735760B2/en
Ceased legal-status Critical Current

Links

GBGB9721266.6A 1997-04-24 1997-10-07 Therapeutic use Ceased GB9721266D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB9721266.6A GB9721266D0 (en) 1997-10-07 1997-10-07 Therapeutic use
PCT/GB1998/001178 WO1998047514A1 (en) 1997-04-24 1998-04-22 Use of an nk-1 receptor antagonist and an ssri for treating obesity
JP54529998A JP2001523245A (en) 1997-04-24 1998-04-22 Use of NK-1 receptor antagonists and SSRIs to treat obesity
CA002287397A CA2287397A1 (en) 1997-04-24 1998-04-22 Use of an nk-1 receptor antagonist and an ssri for treating obesity
EP98917442A EP0977573A1 (en) 1997-04-24 1998-04-22 Use of an nk-1 receptor antagonist and an ssri for treating obesity
US09/403,519 US6162805A (en) 1997-04-24 1998-04-22 Use of an NK-1 receptor antagonist and an SSRI for treating obesity
AU70671/98A AU735760B2 (en) 1997-04-24 1998-04-22 Use of a NK-1 receptor antagonist and an SSRI for treating obesity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721266.6A GB9721266D0 (en) 1997-10-07 1997-10-07 Therapeutic use

Publications (1)

Publication Number Publication Date
GB9721266D0 true GB9721266D0 (en) 1997-12-10

Family

ID=10820183

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9721266.6A Ceased GB9721266D0 (en) 1997-04-24 1997-10-07 Therapeutic use

Country Status (1)

Country Link
GB (1) GB9721266D0 (en)

Similar Documents

Publication Publication Date Title
GB9708484D0 (en) Therapeutic agents
GB9708945D0 (en) Therapeutic agents
GB9704948D0 (en) Therapeutic agents
ZA982368B (en) New therapeutic combinations
GB9702524D0 (en) Therapeutic agents
GB9711753D0 (en) Therapeutic agents
GB9713707D0 (en) Therapeutic agents
GB9715977D0 (en) Therapeutic agents
GB9711114D0 (en) Therapeutic agents
GB9702392D0 (en) Therapeutic agents
GB9620777D0 (en) Therapeutic use
GB9700555D0 (en) Therapeutic agents
GB9723999D0 (en) Therapeutic use
GB9726701D0 (en) Therapeutic use
GB9726702D0 (en) Therapeutic use
GB9716457D0 (en) Therapeutic agents
GB9721265D0 (en) Therapeutic use
GB9708288D0 (en) Therapeutic use
GB9721192D0 (en) Therapeutic use
GB9721191D0 (en) Therapeutic use
GB9721190D0 (en) Therapeutic use
GB9721179D0 (en) Therapeutic use
GB9721266D0 (en) Therapeutic use
GB9721173D0 (en) Therapeutic use
GB9721177D0 (en) Therapeutic use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)